傲農生物(603363.SH):擬申請再新增15億授信額度
格隆匯 8 月 31日丨傲農生物(603363.SH)公佈,公司第二屆董事會第二十二次會議及2020年第三次臨時股東大會審議通過《關於2020年度向金融機構申請融資授信額度的議案》,同意公司(包括公司下屬全資、控股子公司)2020年繼續向包括但不限於銀行、融資租賃公司等金融機構申請融資授信,申請授信額度為不超過人民幣35億元,此次申請融資授信額度的決議有效期為自2020年第三次臨時股東大會審議通過之日起至2020年年度股東大會召開之日止。
現根據公司融資需要,為滿足公司日常生產經營和建設發展所需的資金需求,公司擬在上述35億元授信額度的基礎上,再新增15億授信額度,即2020年向金融機構申請融資授信額度為不超過人民幣50億元。調整後的融資授信額度的決議有效期為自本事項經股東大會審議通過之日起至2020年年度股東大會召開之日止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.